Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting.
about
Current Strategies for the Detection of Minimal Residual Disease in Childhood Acute Lymphoblastic LeukemiaMinimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologiesNew criteria for response assessment: role of minimal residual disease in multiple myelomaDevelopment of personalized tumor biomarkers using massively parallel sequencingDetection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencingImproving cancer outcomes through international collaboration in academic cancer treatment trials.CREBBP HAT domain mutations prevail in relapse cases of high hyperdiploid childhood acute lymphoblastic leukemiaAugmented therapy improves outcome for pediatric high risk acute lymphocytic leukemia: results of Children's Oncology Group trial P9906.Bone Marrow Recovery by Morphometry during Induction Chemotherapy for Acute Lymphoblastic Leukemia in Children.Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232.Time point-dependent concordance of flow cytometry and real-time quantitative polymerase chain reaction for minimal residual disease detection in childhood acute lymphoblastic leukemia.Quantification of minimal residual disease (MRD) in acute lymphoblastic leukemia (ALL) using amplicon-fusion-site polymerase chain reaction (AFS-PCR)Monitoring of minimal residual disease (MRD) is useful to predict prognosis of adult patients with Ph-negative ALL: results of a prospective study (ALL MRD2002 Study)Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study.Determining the repertoire of IGH gene rearrangements to develop molecular markers for minimal residual disease in B-lineage acute lymphoblastic leukemia.Sensitive and specific measurement of minimal residual disease in acute lymphoblastic leukemia.A simplified minimal residual disease polymerase chain reaction method at early treatment points can stratify children with acute lymphoblastic leukemia into good and poor outcome groupsMalleable immunoglobulin genes and hematopathology - the good, the bad, and the ugly: a paper from the 2007 William Beaumont hospital symposium on molecular pathologyEstablishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM090Minimal Residual Disease Detection and Evolved IGH Clones Analysis in Acute B Lymphoblastic Leukemia Using IGH Deep Sequencing.Detection of minimal residual disease in B lymphoblastic leukemia by high-throughput sequencing of IGH.In childhood acute lymphoblastic leukemia, blasts at different stages of immunophenotypic maturation have stem cell properties.Minimal residual disease analysis by eight-color flow cytometry in relapsed childhood acute lymphoblastic leukemia.Risk assessment of relapse by lineage-specific monitoring of chimerism in children undergoing allogeneic stem cell transplantation for acute lymphoblastic leukemiaComparison between qualitative and real-time polymerase chain reaction to evaluate minimal residual disease in children with acute lymphoblastic leukemiaHighly sensitive MRD tests for ALL based on the IKZF1 Δ3-6 microdeletion.
P2860
Q26751269-997BB157-E420-44F9-B1E8-1A4A68BDBA4BQ26828511-1B11F87F-A115-4371-9458-F977F3750A55Q27027512-FD3B0709-33DC-46B5-8520-AEA2A68F2B4BQ28278819-839588DE-0E0A-413A-8526-F7CDEC61D13EQ28280303-BB501D03-E910-4556-86F1-328B9E603FFFQ33561197-4D06153B-C5A7-4EF0-A931-E08C1B57FC56Q34325522-6C67CB86-0A07-4A9D-A6F8-318F9E1FB608Q35106033-723A02F1-7F64-4CE7-BC42-6FEBDA27586AQ35593356-1013D887-FDEB-4A3A-95CE-0D85DC9992B3Q35976588-29C925EA-E88D-4BEB-960F-238AB94426ECQ36366977-716C5519-6724-46A6-B75F-536797D06093Q36455812-B896968A-F862-4728-A5A7-1E9D70589067Q36616666-C41A9989-B627-499C-9212-3FF2D6A1B0ADQ36713493-3E72B784-A3BE-434F-8487-19A940FA8464Q37164456-489C9B04-FF1E-4D65-BB1D-09C0E3041A11Q37164460-D487B35A-8C3B-4937-B2CD-52D2A59915AFQ37207757-119664AD-D472-47C4-8A04-39351AD316A9Q37238171-6FB2F9D2-80B0-445F-B8E8-181ED2BE48A2Q37250169-A2656EBD-0026-4E1D-8997-102E3861F8BDQ37307811-C93F73FD-BE9F-4493-8B26-98313CF16BCBQ37481981-3F2661B1-D1A9-4775-BE11-A03378649700Q39965610-46E49338-E378-437B-B696-01F643B4EBA9Q40910460-12529946-8884-466F-8FE5-1B36DFCE205CQ41032396-7B98038B-C587-4AFB-9364-0CE1A93D07A3Q41986599-7DFB5751-02FA-48D1-9134-F8CA3DD7E13CQ43201113-76582FDB-753E-40AB-83B5-6F37A17B7778
P2860
Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Optimization of PCR-based mini ...... mia in a multi-center setting.
@en
Optimization of PCR-based mini ...... mia in a multi-center setting.
@nl
type
label
Optimization of PCR-based mini ...... mia in a multi-center setting.
@en
Optimization of PCR-based mini ...... mia in a multi-center setting.
@nl
prefLabel
Optimization of PCR-based mini ...... mia in a multi-center setting.
@en
Optimization of PCR-based mini ...... mia in a multi-center setting.
@nl
P2093
P356
P1433
P1476
Optimization of PCR-based mini ...... emia in a multi-center setting
@en
P2093
Bartram CR
Cazzaniga G
Panzer-Grümayer ER
Schrappe M
Schrauder A
P2888
P304
P356
10.1038/SJ.LEU.2404535
P577
2007-02-08T00:00:00Z